CeriBell, Inc. (CBLL)
(Delayed Data from NSDQ)
$12.91 USD
+0.33 (2.62%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $12.92 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CBLL 12.91 +0.33(2.62%)
Will CBLL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CBLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CBLL
CBLL Stock Falls Despite FDA Clearance for Pediatric Clarity Algorithm
CBLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CBLL
CeriBell GAAP EPS of -$0.38 beats by $0.02, revenue of $21.2M beats by $0.75M
Ceribell outlines $85M–$88M 2025 revenue target while expanding pediatric and neonate pilots
CeriBell, Inc. (CBLL) Q2 2025 Earnings Call Transcript
Ceribell (CBLL) Boosts Revenue Forecast for 2025
Ceribell (CBLL) Surpasses Q2 Revenue Expectations, Plans for Future Expansion